| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Carcinogenesis |
National Cancer Institute, NIH, Bethesda, Maryland 20892 [R. L. D., M. C. P.]; and Institute of Cancer Research, Sutton, Surrey SM2 5NG, United Kingdom [M. R. O., A. H., D. H. P.]
Tamoxifen (TAM), a nonsteroidal antiestrogen used as a chemotherapeutic and chemopreventive agent for breast cancer, induces liver tumors in rodents and covalent DNA adduct formation in hepatic DNA. Here, we report the development and validation of highly sensitive and specific immunoassays for the determination of TAM-DNA adducts. Rabbits were immunized with calf thymus DNA, chemically modified with 
-acetoxytamoxifen to 2.4 adducts per 100 nucleotides, and the resulting antisera were characterized by competitive dissociation-enhanced lanthanide fluoroimmunoassay (DELFIA) and chemiluminescence immunoassay (CIA). Compared with DELFIA, the CIA has a much lower background and a 20-fold increase in sensitivity. For the immunogen TAM-DNA, 50% inhibition was at 2.0 ± 0.11 (mean ± SE, n = 18) fmol of (E)--(N2-deoxyguanosinyl)tamoxifen (TAM-dG) adduct in TAM-DNA by DELFIA. For TAM-DNA modified to 4.8 adducts in 106 nucleotides, 50% inhibition was at 20.6 ± 6.6 (mean ± SE, n = 8) fmol of TAM-dG in TAM-DNA by DELFIA and at 0.92 ± 0.11 (mean ± SE, n = 10) fmol of TAM-dG in TAM-DNA by CIA. No inhibition was observed in either assay with up to 20 µg (62.5 nmol of nucleotides) of unmodified DNA. The individual adducts TAM-dG and (Z)--(N2-deoxyguanosinyl)tamoxifen and the individual compounds TAM and 4-OH-TAM gave DELFIA 50% inhibitions at 828, 2229, 5440, and 8250 fmol, respectively. For assay validation, TAM-dG levels were determined by DELFIA, CIA, and 32P-postlabeling in TAM-DNA samples modified in vitro to different levels, and comparable values were obtained in all three assays. Further validation was obtained in vivo in rat liver. DNA adducts of TAM were measurable in rat liver 24 h after a single i.p. dose of 45 mg TAM/kg body weight and after daily p.o. dosing for 7 days with 5.0, 10.0, and 20.0 mg TAM/kg body weight. In addition, TAM-DNA adducts disappeared slowly over 21 days in rats on a control diet that were first given p.o. TAM at 45 mg/kg/day for 4 days. In the rat experiments, TAM-DNA adduct levels determined by CIA compared well with those determined by 32P-postlabeling, although the CIA gave an underestimation at the highest doses. For rat liver samples, the detection limit by CIA was 3 adducts per 109 nucleotides (0.2 fmol of adducts per 20 µg of DNA).
This article has been cited by other articles:
|
|
 |
|
  H. E. van Gijssel, T. A. Leil, W. C. Weinberg, R. L. Divi, O. A. Olivero, and M. C. Poirier Cisplatin-DNA damage in p21WAF1/Cip1 deficient mouse keratinocytes exposed to cisplatin Mutagenesis, January 1, 2007; 22(1): 49 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. P. Tryndyak, L. Muskhelishvili, O. Kovalchuk, R. Rodriguez-Juarez, B. Montgomery, M. I. Churchwell, S. A. Ross, F. A. Beland, and I. P. Pogribny Effect of long-term tamoxifen exposure on genotoxic and epigenetic changes in rat liver: implications for tamoxifen-induced hepatocarcinogenesis Carcinogenesis, August 1, 2006; 27(8): 1713 - 1720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Y. Kim, N. Suzuki, Y. R. S. Laxmi, and S. Shibutani INEFFICIENT REPAIR OF TAMOXIFEN-DNA ADDUCTS IN RATS AND MICE Drug Metab. Dispos., February 1, 2006; 34(2): 311 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Schild, D. H. Phillips, M. R. Osborne, A. Hewer, F. A. Beland, M. I. Churchwell, K. Brown, M. Gaskell, E. Wright, and M. C. Poirier Hepatic DNA adduct dosimetry in rats fed tamoxifen: a comparison of methods Mutagenesis, March 1, 2005; 20(2): 115 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Schild, R. L. Divi, F. A. Beland, M. I. Churchwell, D. R. Doerge, G. Gamboa da Costa, M. M. Marques, and M. C. Poirier Formation of Tamoxifen-DNA Adducts in Multiple Organs of Adult Female Cynomolgus Monkeys Dosed with Tamoxifen for 30 Days Cancer Res., September 15, 2003; 63(18): 5999 - 6003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shibutani, N. Suzuki, Y. R. S. Laxmi, L. J. Schild, R. L. Divi, A. P. Grollman, and M. C. Poirier Identification of Tamoxifen-DNA Adducts in Monkeys Treated with Tamoxifen Cancer Res., August 1, 2003; 63(15): 4402 - 4406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Poirier and L. J. Schild The Genotoxicity of Tamoxifen: Extent and Consequences, Kona, Hawaii, January 23, 2003 Mutagenesis, July 1, 2003; 18(4): 395 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. E. van Gijssel, R. L. Divi, O. A. Olivero, M. J. Roth, G.-Q. Wang, S. M. Dawsey, P. S. Albert, Y.-L. Qiao, P. R. Taylor, Z.-W. Dong, et al. Semiquantitation of Polycyclic Aromatic Hydrocarbon-DNA Adducts in Human Esophagus by Immunohistochemistry and the Automated Cellular Imaging System Cancer Epidemiol. Biomarkers Prev., December 1, 2002; 11(12): 1622 - 1629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Divi, F. A. Beland, P. P. Fu, L. S. Von Tungeln, B. Schoket, J. E. Camara, M. Ghei, N. Rothman, R. Sinha, and M. C. Poirier Highly sensitive chemiluminescence immunoassay for benzo[a]pyrene-DNA adducts: validation by comparison with other methods, and use in human biomonitoring Carcinogenesis, December 1, 2002; 23(12): 2043 - 2049. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Divi, Y. P. Dragan, H. C. Pitot, and M. C. Poirier Immunohistochemical localization and semi-quantitation of hepatic tamoxifen-DNA adducts in rats exposed orally to tamoxifen Carcinogenesis, October 1, 2001; 22(10): 1693 - 1699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Gamboa da Costa, L.P. McDaniel-Hamilton, R. H. Heflich, M.M. Marques, and F. A. Beland DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives Carcinogenesis, August 1, 2001; 22(8): 1307 - 1315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Phillips Understanding the genotoxicity of tamoxifen? Carcinogenesis, June 1, 2001; 22(6): 839 - 849. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shibutani, A. Ravindernath, I. Terashima, N. Suzuki, Y. R. Santosh Laxmi, Y. Kanno, M. Suzuki, T. I. Apak, J. J. Sheng, and M. W. Duffel Mechanism of Lower Genotoxicity of Toremifene Compared with Tamoxifen Cancer Res., May 1, 2001; 61(10): 3925 - 3931. [Abstract] [Full Text]
|
|
|
|
|
|
S. Shibutani, A. Ravindernath, N. Suzuki, I. Terashima, S. M. Sugarman, A. P. Grollman, and M. L. Pearl Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen Carcinogenesis, August 1, 2000; 21(8): 1461 - 1467. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
